XOMA to Present at Upcoming Investor Conferences in March

2024-02-28

EMERYVILLE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following March 2024 investor conferences: The 44th Annual TD Cowen Health Care Conference taking place March 4-6, 2024, in Boston, MA. Owen Hughes, Chief Executive Officer, and Brad Sitko, Chief Investment Officer, will be featured in a fireside chat on Wednesday, March 6, 2024, at 10:30 AM ET. The presentation can be accessed at . The Leerink Partners 2024 Global Biopharma Conference, which is being held March 11-13, 2024, in Miami, FL. Mr. Hughes will present the corporate overview on Monday, March 11, 2024, at 10:40 AM ET. The presentation can be accessed at . XOMA’s presentations can also be accessed by visiting the investor relations section of the Company’s website at . A replay of each presentation will be available and archived on the site for 90 days after the event. About XOMA Corporation XOMA is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio with more than 70 assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit XOMA Investor Contact XOMA Media Contact Juliane Snowden Kathy Vincent XOMA Corporation KV Consulting & Management +1 646-438-9754 +1 310-403-8951 juliane.snowden@xoma.com kathy@kathyvincent.com

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构